You are here

DELPOR INC

Company Information
Address
150 N HILL DR STE 25
BRISBANE, CA 94005-1019
United States


https://www.delpor.com/

Information

UEI: MJXNYJ6Q4GM8

# of Employees: 10


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. Sustained Delivery of Tizanidine for Maintenance Treatment of Moderate to Severe Spasticity

    Amount: $2,527,179.00

    Spasticity is an increase in muscle tone and uncontrolled, repetitive, involuntary contractions of skeletal muscles. Spasticity presents as upper motor neuron symptoms in patients with central nervous ...

    SBIRPhase II2021Department of Health and Human Services National Institutes of Health
  2. Sustained 3-Month Delivery of Tizanidine for Maintenance Treatment of Moderate to Severe Spasticity

    Amount: $224,798.00

    Spasticity is an increase in muscle tone and uncontrolledrepetitiveinvoluntary contractions of skeletal musclesSpasticity presents as upper motor neuron symptoms in patients with central nervous syste ...

    SBIRPhase I2019Department of Health and Human Services National Institutes of Health
  3. Risperidone Subcutaneous Implant

    Amount: $6,037,027.00

    The objective of the proposed study is to develop a subcutaneous implant of risperidone that provides consistent therapeutic blood levels of the drug for 6 months after a single administration. The de ...

    SBIRPhase II2019Department of Health and Human Services National Institutes of Health
  4. Sustained Month Delivery of Olanzapine for Schizophrenia Maintenance Treatment

    Amount: $224,389.00

    Lack of medication adherence has been shown to correlate strongly with relapse and re hospitalization during schizophrenia maintenance treatment With each successive relapse the patientandapos s lon ...

    SBIRPhase I2017Department of Health and Human Services National Institutes of Health
  5. Sustained 3-Month Delivery of Stabilized Exenatide Through Nanopore Membranes for Type 2 Diabetes Therapy

    Amount: $1,475,430.00

    The prevalence of Typediabetes is expected to reachbyand according to the Centers for Disease Control and Preventionas many asinU Sadults could have diabetes byIn the lastyearsa new class of drugscall ...

    SBIRPhase II2017Department of Health and Human Services National Institutes of Health
  6. Sustained 3-Month Delivery of Stabilized Exenatide Through Nanopore Membranes for

    Amount: $222,459.00

    DESCRIPTION (provided by applicant): The prevalence of Type 2 diabetes is expected to reach 20%-30% by 2050. In the last 8 years, a new class of drugs, called incretin mimetics, has been used successf ...

    SBIRPhase I2014Department of Health and Human Services National Institutes of Health
  7. Risperidone Subcutaneous Implant

    Amount: $3,009,671.00

    DESCRIPTION provided by applicant The objective of the proposed study is to develop a subcutaneous implant of risperidone which provides consistent therapeutic blood levels of the drug for months ...

    SBIRPhase II2013Department of Health and Human Services National Institutes of Health
  8. Risperidone Subcutaneous Implant

    Amount: $344,211.00

    DESCRIPTION (provided by applicant): The objective of the proposed study is to develop a subcutaneous implant of risperidone which provides consistent therapeutic blood levels of the drug for 3 months ...

    SBIRPhase I2012Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government